Radient presents Onko-Sure® data; Alkermes Announces Results From Phase Two Study Print E-mail
By Staff and Wire Reports   
Thursday, 07 July 2011 19:35
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 7, 2011.

Radient Pharmaceuticals Corporation, (OTCQX: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, announced researchers at the University of Chile, CeTeCancer (Center for Cancer Technologies), presented a scientific poster and clinical research findings at the 14th Annual World Conference on Lung Cancer in Amsterdam. The poster included information relevant to the clinical utility of Onko-Sure® DR-70® ("DR-70") in the early detection of lung cancer.

The poster was presented at the session for Prognostic and Predictive Markers. Titled, "Detection of Pre-Invasive and Pre-Neoplasic Lesions Using Biological and Genomic Lung Cancer Biomarkers in a High Risk Chilean Population," the poster's abstract was published in the Journal of Thoracic Oncology Volume (6), S980.

The researchers used RPC's Onko-Sure® test as one of two blood tests in their clinical trial on the early detection of lung cancer. The other blood test used was based on a genomic biomarker using SNPs (single nucleotide polymorphisms). The published poster presented information that supports the sensitivity of Onko-Sure® DR-70® to be 90% for confirmed lung cancer patients. Furthermore, in the cohort of high-risk patients for lung cancer, sputum cytology and the Onko-Sure® DR-70® assay were reliable predictors of the outcome of autofluorescent bronchoscopy (AFB), which is a more invasive and expensive procedure. A high percentage of patients with abnormal sputum cytology and positive Onko-Sure® DR-70® showed suspicious images with autofluorescent bronchoscopy (AFB), and were confirmed later as pre malignant lesions and/or inflammation.

"These independent research results further validate our Onko-Sure® test as a clinically useful tool in the early detection of one of the most fatal cancers. It is our aim to move this test towards commercialization. The ability to detect lung cancer at its earliest stages could make a significant and favorable shift in survival rates," stated Radient Pharmaceuticals Chairman and CEO Douglas MacLellan.

===

Alkermes, Inc. (NASDAQ:ALKS) announced topline results from a phase two clinical study of ALKS 33 in the treatment of binge eating disorder.

This randomized, double-blind, placebo-controlled, 12-week study was designed to assess the safety and efficacy of daily oral administration of ALKS 33 or placebo in 68 patients with binge eating disorder. While ALKS 33 demonstrated a significant reduction from baseline in the efficacy endpoint of self-reported weekly binge eating episodes, the reduction was not significantly different from that observed with placebo.

Based on these results, the Company has determined that future studies in the binge eating indication are less attractive than other potential alternatives and will not pursue further development of ALKS 33 in this area.

ALKS 33 remains in development for other central nervous system indications based on the compound’s favorable characteristics of once-daily dosing, limited hepatic metabolism and durable pharmacologic activity in modulating brain opioid receptors.

The phase two, randomized, double-blind, placebo-controlled, 12-week study was designed to assess the safety and efficacy of daily oral administration of ALKS 33 in 68 patients with binge eating disorder. Binge eating episodes were defined using DSM-IV-TR1 criteria and assessed based on interviews and review of take-home diaries at weekly physician visits.


Also Thursday:


Cepheid (Nasdaq:CPHD)
today announced that it will report financial results for its 2011 second quarter ended June 30, 2011, on Thursday, July 21, 2011, after the close of the market.

Cord Blood America, Inc. (OTC Bulletin Board:CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced today that CorCell, its domestic brand for cord blood stem cell collection and storage, has a launched a new Referral Rewards Program in the U.S. for the collection of a baby's umbilical cord blood.

Derycz Scientific, Inc. (OTC BB: DYSC) today announced that its fully owned subsidiary Reprints Desk Inc. has signed a deal with Oriprobe Information Services, Inc., that enables Reprints Desk to source and deliver Oriprobe’s collection of Chinese, Japanese, Korean and other Asian journals. Derycz Scientific subsidiaries delivered millions of articles to more than 100 countries, including many within Asia, during the last fiscal year in part due to growing demand for Chinese and other non-English content.

IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC) and formerly (OTCQB: CWLC) (PINKSHEETS: CWLC) ("IntelliCell" or the "Company"), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, today announced that it has changed its name from Media Exchange Group, Inc. to IntelliCell BioSciences, Inc., effective June 27, 2011.

InterMune (NASDAQ:ITMN) today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis (IPF).

Life Technologies Corporation (NASDAQ:LIFE) announced today it will report its second quarter 2011 financial results on Thursday, July 28, 2011, before market open.

Medizone International, Inc. (OTCBB: MZEI) (OTCQB: MZEI) proudly announces that its flagship disinfection technology, AsepticSure™, has won a prestigious international award for innovation.

Radient Pharmaceuticals Corporation (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, announced today that researchers at the University of Chile, CeTeCancer (Center for Cancer Technologies), presented a scientific poster and clinical research findings at the 14th Annual World Conference on Lung Cancer in Amsterdam.

SAFC®, a member of the Sigma-Aldrich® Group (NASDAQ:SIAL), today announced the launch of the first offering in a product line of Zinc Finger Nuclease (ZFN)-modified Chinese Hamster Ovary (CHO) cell lines.

Shire plc (LSE: SHP, NASDAQ:SHPGY), the global specialty biopharmaceutical company, announces that it has filed lawsuits in the U.S. District Court for the District of New Jersey against Roxane Laboratories, Inc., ("Roxane"), and in the U.S. District Court for the Central District of California against Watson Laboratories, Inc., ("Watson"), respectively, for infringement of certain of Shire's VYVANSE patents.

YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM) (the "Company"), today announced it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Canada and a registration statement on Form F-10 with the United States Securities and Exchange Commission.

Waters Corporation (NYSE:WAT) today welcomed the metabolomics program at Georgetown University Medical Center (GUMC) into its Centers of Innovation Program and recognized Albert J. Fornace Jr., MD, and Amrita Cheema, PhD, the directors of this pioneering program at Georgetown Lombardi Comprehensive Cancer Center, part of GUMC, in Washington, DC.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter